MCID: WDH001
MIFTS: 28

Wdha Syndrome malady

Categories: Rare diseases, Endocrine diseases

Aliases & Classifications for Wdha Syndrome

Aliases & Descriptions for Wdha Syndrome:

Name: Wdha Syndrome 50 52
Pancreatic Cholera 50 69
Watery Diarrhea, Hypokalemia, and Achlorhydria Syndrome 50
Verner-Morrison Syndrome 50

Classifications:



Summaries for Wdha Syndrome

MalaCards based summary : Wdha Syndrome, also known as pancreatic cholera, is related to pheochromocytoma and vipoma. An important gene associated with Wdha Syndrome is VIP (Vasoactive Intestinal Peptide), and among its related pathways/superpathways are Neuroscience and G alpha (s) signalling events. The drugs pancreatic polypeptide and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include pancreas, pancreatic islet and lung.

Related Diseases for Wdha Syndrome

Diseases related to Wdha Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 42)
id Related Disease Score Top Affiliating Genes
1 pheochromocytoma 29.5 CALCA SST VIP
2 vipoma 11.2
3 pancreatic cholera 10.8
4 pancreatitis 10.1
5 placenta accreta 10.0 CALCA VIP
6 cockayne syndrome type i 10.0 CALCA VIP
7 cough variant asthma 10.0 CALCA VIP
8 lipid-rich carcinoma 10.0 CALCA VIP
9 pemphigus foliaceus 10.0 CALCA SST
10 paranasal sinus cancer, adult 10.0 CALCA SST
11 brain ependymoma 10.0 CALCA SST
12 lung occult small cell carcinoma 10.0 CALCA SST
13 diarrhea 10.0
14 hypokalemia 10.0
15 cowden syndrome 3 9.9 CALCA SST
16 choline deficiency disease 9.9 SST VIP
17 gmppa-cdg 9.9 SST VIP
18 cardioauditory syndrome of sanchez cascos 9.9 CALCA SST
19 inflammatory diarrhea 9.9 SST VIP
20 drug psychosis 9.9 SST VIP
21 acute pyelonephritis 9.9 SST VIP
22 maturity-onset diabetes of the young, type 13 9.9 SST VIP
23 axial osteomalacia 9.9 CALCA SST
24 bone dysplasia azouz type 9.9 SST VIP
25 myoepithelial carcinoma 9.9 SST VIP
26 bile acid synthesis defect, congenital, 4 9.8 SST VIP
27 neutropenia, severe congenital, 5, autosomal recessive 9.8 CALCA SST
28 muscular dystrophy-dystroglycanopathy , type a, 10 9.8 CALCA SST
29 sweat gland cancer 9.8 SST VIP
30 band keratopathy 9.8 SST VIP
31 wells-jankovic syndrome 9.8 CALCA SST VIP
32 volkmann contracture 9.7 CALCA SST VIP
33 spinal stenosis 9.7 CALCA SST VIP
34 gemistocytic astrocytoma 9.7 CALCA SST VIP
35 keloids 9.7 CALCA SST VIP
36 benign shuddering attacks 9.7 CALCA SST VIP
37 mitochondrial dna depletion syndrome 5 9.7 CALCA SST VIP
38 endocrine gland cancer 9.7 CALCA SST
39 neurofibromatosis, type 1 9.7
40 ganglioneuroblastoma 9.7
41 adenoma 9.7
42 neurofibromatosis 9.7

Graphical network of the top 20 diseases related to Wdha Syndrome:



Diseases related to Wdha Syndrome

Symptoms & Phenotypes for Wdha Syndrome

Drugs & Therapeutics for Wdha Syndrome

Drugs for Wdha Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
3
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
4
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
5
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
6
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
10 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
11 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
12 Immunosuppressive Agents Phase 2, Phase 3
13 Antimetabolites Phase 2, Phase 3,Phase 1
14 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
15 Analgesics Phase 3
16 Adjuvants, Anesthesia Phase 3
17 Narcotics Phase 3
18 Analgesics, Opioid Phase 3
19 Anesthetics Phase 3
20 Anesthetics, General Phase 3
21 Anesthetics, Intravenous Phase 3
22 Peripheral Nervous System Agents Phase 3
23 Central Nervous System Depressants Phase 3
24 Folate Nutraceutical Phase 2, Phase 3
25 Vitamin B9 Nutraceutical Phase 2, Phase 3
26 Cola Nutraceutical Phase 3,Phase 2,Phase 1
27
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
28
Melphalan Approved Phase 2 148-82-3 4053 460612
29
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
30
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
31
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
32
Pancrelipase Approved Phase 2 53608-75-6
33
Somatostatin Approved Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
34
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
35
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
36
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
37 pancreatin Phase 2
38 Alkylating Agents Phase 2
39 topoisomerase I inhibitors Phase 2
40 Gastrointestinal Agents Phase 2,Phase 1
41 Nicotinic Acids Phase 2
42 Topoisomerase Inhibitors Phase 2
43 Trace Elements Phase 2
44 Hormones Phase 2,Phase 1
45 Vitamin B Complex Phase 2
46 Anti-Bacterial Agents Phase 2
47 Vitamins Phase 2
48 Anti-Infective Agents Phase 2
49 Protective Agents Phase 2,Phase 1
50 Antidotes Phase 2,Phase 1

Interventional clinical trials:

(show all 16)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
4 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2
5 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2
6 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2
7 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2
8 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2
9 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2
10 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2
11 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2
12 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
13 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
14 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1
15 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1
16 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1

Search NIH Clinical Center for Wdha Syndrome

Genetic Tests for Wdha Syndrome

Anatomical Context for Wdha Syndrome

MalaCards organs/tissues related to Wdha Syndrome:

39
Pancreas, Pancreatic Islet, Lung

Publications for Wdha Syndrome

Articles related to Wdha Syndrome:

(show all 25)
id Title Authors Year
1
Hypokalemic rhabdomyolysis due to watery diarrhea, hypokalemia, achlorhydria (WDHA) syndrome caused by vipoma. ( 19488018 )
2009
2
VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome. ( 19184565 )
2009
3
A Pancreatic Polypeptide-Producing Pancreatic Tumor Causing WDHA Syndrome. ( 21490894 )
2008
4
Hypokalemic rhabdomyolysis due to WDHA syndrome caused by VIP-producing composite pheochromocytoma: a case in neurofibromatosis type 1. ( 16027147 )
2005
5
A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome. ( 14716055 )
2003
6
A multihormonal tumor of the pancreas producing neurotensin associated with the WDHA syndrome. Histology, histochemistry and origin. ( 2856535 )
1986
7
Pancreatic endocrine tumours associated with WDHA syndrome. An immunohistochemical and electron microscopic study. ( 2579503 )
1985
8
The WDHA syndrome: clinical and laboratory data on 28 Japanese cases. ( 6473165 )
1984
9
The exocrine pancreas of patients with WDHA syndrome. A light and electron microscopical study. ( 6471149 )
1984
10
WDHA syndrome caused by VIP-producing ganglioneuroblastoma. ( 6288909 )
1982
11
Angiographic diagnosis of a pancreatic islet tumor in a patient with the WDHA syndrome. ( 6252088 )
1980
12
Effects of streptozotocin in the WDHA syndrome not amenable to radical surgery. ( 6152975 )
1980
13
Effects fo streptozotocin in the WDHA syndrome not amenable to radical surgery. ( 6253557 )
1980
14
Clinical and hormonal aspects of the watery diarrhea-hypokalemia-achlorhydria (WDHA) syndrome due to vasoactive intestinal polypeptide (VIP)-producing tumor. ( 7014208 )
1980
15
VIP and the WDHA syndrome. ( 437409 )
1979
16
Angiographic demonstration of a vasoactive intestinal polypeptide-secreting pheochromocytoma in a patient with WDHA syndrome. ( 413408 )
1978
17
WDHA syndrome caused by pheochromocytoma: report of a case. ( 657943 )
1978
18
A pancreatic-polypeptide-producing tumour associated with the WDHA syndrome. ( 151327 )
1978
19
The VIPoma: further confirmation of VIP as the hormonal agent in the WDHA syndrome. ( 998869 )
1976
20
Watery diarrhoea (WDHA) syndrome associated with carcinoma of the lung. ( 193482 )
1976
21
Angiographic demonstration of a pancreatic "vipoma" in the WDHA syndrome. ( 187070 )
1976
22
Radiologic and pathologic characteristics of the WDHA syndrome. ( 183523 )
1976
23
Editorial: WDHA-syndrome and gastric secretory inhibitors. ( 4851596 )
1974
24
Bioassay for gastric secretory inhibitor in extract of pancreatic tumour from patient with WDHA-syndrome. ( 5455828 )
1970
25
Islet-cell adenoma of the pancreas with reversible watery diarrhea and hypokalemia. WDHA syndrome. ( 4313557 )
1970

Variations for Wdha Syndrome

Expression for Wdha Syndrome

Search GEO for disease gene expression data for Wdha Syndrome.

Pathways for Wdha Syndrome

Pathways related to Wdha Syndrome according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.47 CALCA VIP
2 10.79 CALCA VIP

GO Terms for Wdha Syndrome

Cellular components related to Wdha Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 8.62 CALCA SST

Biological processes related to Wdha Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 8.96 CALCA SST
2 response to heat GO:0009408 8.62 CALCA SST

Molecular functions related to Wdha Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CALCA SST VIP

Sources for Wdha Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....